Reported Ozempic Side Effects in Females

Some people are more likely to experience side effects from medications, and women often fall into this group. Studies show that women face a 1.5 to 1.7 times higher chance of adverse drug reactions compared to men.

This becomes especially important with drugs like Ozempic (semaglutide). While Ozempic is well-known for helping manage type 2 diabetes, many women report side effects that are often downplayed or misunderstood.

This guide explains the side effects women often experience with Ozempic, using both clinical research and real-world reports. It also shows what’s normal, when to be concerned, and how to respond.

Why do women react differently to Ozempic?

Current evidence suggests several possible reasons, such as:

Slower gastric emptying

Ozempic supports weight loss by slowing how quickly food leaves the stomach. This keeps you fuller for longer and can reduce how much you eat.

If your stomach already empties slowly, adding Ozempic may make symptoms worse. You could notice more nausea, bloating, or a sense of fullness after only a small amount of food. Vomiting and other stomach issues may also be more likely, especially when doses increase.

Reviews of existing studies suggest that women generally have slower gastric emptying than men. Hormones such as estrogen and progesterone, and higher nitric oxide levels, may be part of the reason. Women are also more likely to develop gastroparesis, a condition marked by very slow stomach emptying, although the exact reasons remain unclear.

Hormonal fluctuations

Hormonal changes in women, such as shifts in estrogen and progesterone during the menstrual cycle, pregnancy, perimenopause, or menopause, may influence how side effects are felt.

In one large study that examined more than 18 million reports across 131 countries, about 60% of side effect reports came from women. The difference appeared as early as adolescence and was most visible among women aged 18 to 44, the typical reproductive years.

Levels of albumin

Semaglutide is a large peptide drug that attaches to albumin, a protein in the blood. This connection allows it to move through the body in a steady, slow-releasing form. Most of it stays in the bloodstream instead of spreading into fat or muscle.

Research shows that women’s albumin levels tend to fall more quickly than men’s, although by around age 60, the levels become similar in both sexes. When albumin is lower, there may be more “free” semaglutide circulating in the blood. The unbound form is more active, which could mean the drug clears faster or feels stronger for a short time.

Still, these ideas remain theoretical. The differences in albumin between men and women have not been studied closely enough in relation to semaglutide, and clinical trials have not confirmed whether they change how the drug works.

Reporting behavior

Research shows women are more likely to notice changes in their health, seek medical attention for side effects, and participate in online discussions or official reporting systems like MedWatch or VigiBase.

Social expectations may encourage women to speak more openly about symptoms with doctors, while men are often less likely to report issues because of stigma or a tendency to endure discomfort silently.

What are the commonly reported Ozempic side effects in females?

Below are the most commonly reported side effects among female users.

1. Changes in the menstrual cycle

Some women notice shifts in their periods after starting Ozempic. Cycles may become irregular, bleeding may be heavier or lighter, or periods may stop altogether. Women with polycystic ovary syndrome (PCOS) sometimes see stronger changes.

Not all of these effects are negative. Extra body fat can disrupt hormone balance, leading to irregular or absent periods. By supporting weight loss and improving insulin sensitivity, Ozempic may restore regular ovulation.

One study showed that women taking semaglutide lost an average of 11.5 kg, dropping their BMI from 34.4 to 29.4. About 80% regained regular menstrual cycles.

A case report described a 20-year-old woman with years of severe menstrual pain, nausea, vomiting, and fainting who found nearly complete relief after starting semaglutide. When she paused treatment, her symptoms returned, and when she restarted, they improved again. This suggests Ozempic may have potential for difficult menstrual conditions, though more research is needed.

In a forum thread, a 40-year-old woman with PCOS shared her experience after starting Ozempic. She explained that throughout her life, she rarely had natural periods, often going years without them unless on birth control. After beginning Ozempic and later stopping birth control, she unexpectedly experienced three consecutive natural menstrual cycles for the first time in her life.

Ozempic and menstruation?
byu/wyldeyz inPCOS

Women in their 20s, 30s, 40s, and even 50s shared stories. Some were postmenopausal or on hormone replacement therapy, yet still noticed the return of bleeding after starting Ozempic. Others in their reproductive years found that ovulation shifted to earlier in the cycle, which in some cases helped with fertility. A few even became pregnant after years of difficulty conceiving.

Many commenters expressed joy and surprise at finally feeling “normal” or having proof of ovulation. Others admitted frustration over years of doctors dismissing their concerns, with Ozempic offering a change they never thought possible. A few users, however, described mixed feelings, such as not wanting a period to return after decades without one.

2. Acne

Early research found GLP-1 users were 36% more likely to develop acne within 90 days and 34% more likely after one year. Women in particular were 53% more likely to develop acne after one year, while men showed no increased risk.

Hormonal changes may explain this. GLP-1 drugs can raise IGF-1 levels, which stimulate oil production and sometimes trigger acne. Women with obesity, especially after menopause, often have higher testosterone levels and may be more sensitive to these changes. People with hidradenitis suppurativa may also be at greater risk.

In a review of 45 studies, researchers did not find proof that GLP-1 drugs directly cause acne. Instead, the hormonal shifts may trigger or worsen acne in some women.

On Reddit, a user planning to start Ozempic asked whether it can cause acne. They had developed severe breakouts on Mounjaro that resolved after stopping, and they were worried Ozempic might do the same.

Did ozempic cause any of you to get acne?
byu/RealityImpossible771 inOzempic

Many described new or worsening acne after starting Ozempic. Breakouts often clustered on the jawline, chin, under the jaw, and upper neck. A few mentioned dozens of pimples at once. Several said flares began in the second month. Some improved only after stopping the drug, usually within a few weeks.

Some compared drugs. A few had acne on Ozempic but not on Mounjaro, while others had the opposite pattern. One switched from Ozempic to Mounjaro and reported no acne on the new medication at a low dose.

3. Hair thinning or shedding

A study from the University of British Columbia found that semaglutide users were 52% more likely to report hair loss than those on bupropion-naltrexone (Contrave), a weight-loss drug. Women had double the risk compared to men.

Doctors think this comes from rapid weight loss, nutrient deficiencies, and the stress that major weight changes put on the body. People who lost more than 20% of their weight were most affected. The hair loss is usually temporary and known as telogen effluvium. It often improves as weight stabilizes.

There are rare reports of semaglutide possibly triggering alopecia areata, an autoimmune hair condition, though the link is uncertain.

On forums such as Reddit, women have described thinning hair or bald spots, sometimes appearing soon after treatment began or after dose increases. Some saw regrowth after stopping Ozempic, while others continued to struggle even after switching medications.

Anyone else loosing hair like crazy? Im going bald
byu/hubbahubbachopchop inOzempic

Many users said their doctors linked the problem to poor nutrition or hormonal changes from weight loss. Emotional distress was common, but others offered reassurance, sharing stories of gradual regrowth and encouraging nutrition checks and medical follow-up.

4. Mood changes or irritability

The reasons behind mood-related side effects of Ozempic are not yet clear. Possible explanations include:

• • changes in brain signaling
  • rapid body changes
  • existing mental health conditions

Novo Nordisk advises doctors to warn patients about possible depression, suicidal thoughts, or unusual mood shifts. One case involved a 40-year-old woman with a history of depression. After starting semaglutide, her mood worsened, and she developed fatigue, slowed thinking, oversleeping, and suicidal thoughts. Her symptoms improved within two weeks of stopping treatment.

A review of safety reports in Europe found that about 65% of psychiatric cases involved women. Fatal outcomes, however, were more often reported in men.

Someone who had been on Ozempic for two months shared that they noticed a change in personality and mood. Previously very social and known as a “party girl,” she now preferred staying home, spending time with family, working out, and avoiding late nights or heavy drinking. While she thought the change might be good for her overall, it felt strange, so she asked if others had experienced something similar.

Hey! Is Ozempic changing your personality/mood?
byu/Outerbankster inOzempic

Several users said they also felt less interested in drinking, partying, or eating unhealthy foods after starting Ozempic. Some described feeling calmer or more focused, while others noticed a flatter or more neutral mood.

A few shared stories of worsened depression, anxiety, or irritability. One person said their normally kind spouse became short-tempered, restless at night, and fatigued. Another said pre-existing mental health issues, like anxiety or bipolar disorder, became more difficult to manage.

5. Breast tenderness or changes

Although uncommon, some women report breast tenderness or changes while on Ozempic. These may be related to hormone shifts linked with weight loss or metabolism. No large studies have confirmed this side effect, but anecdotal reports suggest it may occur in some women.

In a Reddit post, a user in their third week of Ozempic noticed sore breasts and wondered if others had experienced the same. At first, they suspected menopause, but the timing seemed to line up with their second injection.

3rd week on ozempic..25 Sore Breasts.
byu/No_Principle_7301 inOzempic

Many women and even some men said they developed breast or nipple tenderness after starting Ozempic, especially in the early weeks or after dose increases. Some described heaviness, aching, or sharp nipple pain that made everyday activities uncomfortable.

Some people were concerned enough to see their doctors. A few were referred for mammograms or ultrasounds to rule out breast disease. Most reported that nothing serious was found.

Is Ozempic safe during pregnancy?

Ozempic is not advised if you are pregnant or planning to become pregnant. Its FDA label recommends stopping the drug at least two months before trying, since it takes time for semaglutide to clear from the body. If pregnancy happens while using Ozempic, it should be stopped as soon as it is recognized.

Animal studies have raised concerns about possible harm to the fetus. In rats, semaglutide exposure during pregnancy led to growth problems, structural changes, and pregnancy loss. Similar outcomes were seen in rabbits and monkeys, especially when the mothers lost a significant amount of weight during treatment.

Human data are very limited. A recent study involving 32 pregnancies exposed to semaglutide did not show a higher rate of birth defects compared with those not exposed. However, because the number of women studied was so small, the findings are not strong enough to be considered reassuring.

At the same time, more women are reporting unexpected pregnancies while taking Ozempic. These so-called “Ozempic babies” are likely linked to weight loss restoring ovulation and fertility, particularly in women with obesity or PCOS. While these are anecdotal stories rather than clinical trials, they point to how improved metabolic health can make it easier to conceive.

What should you do if you notice these side effects?

Do not wait until side effects feel overwhelming. Ask about adjusting the pace of your dose increases, since many women find that slowing titration reduces how strongly these effects appear.

Request targeted blood work if symptoms linger. Checking hormone levels, thyroid function, and nutrient status can reveal imbalances that are often correctable.

Specialist input can also be valuable. A gynecologist may help with cycle changes, a dermatologist with skin or hair concerns, and a mental health provider with mood stability. These referrals often uncover options beyond simply stopping the drug. In the meantime, supportive measures can help the body adjust, including:

• • stress tracking
  • consistent sleep
  • nutrition to prevent deficiencies

Importantly, stay alert for red flags. Severe or rapidly worsening symptoms, especially those that disrupt daily life, should be brought up right away. Your healthcare provider can then decide whether dose adjustment, additional treatment, or a change in therapy is the safest next step.

The bottom line

Women can react differently to Ozempic. Common issues include changes in periods, acne, hair loss, mood shifts, and breast tenderness. Some women see benefits like restored cycles or improved fertility, while others face challenges that affect daily life.

If side effects appear, do not ignore them. Ask about slower dose increases, request blood tests, and see specialists for targeted support. Severe or worsening symptoms need quick medical attention so treatment can be adjusted safely.

Frequently Asked Questions

Sources

Rademaker, M. (2001). Do women have more adverse drug reactions? American Journal of Clinical Dermatology, 2(6), 349–351. https://doi.org/10.2165/00128071-200102060-00001

Weaving, G., Batstone, G. F., & Jones, R. G. (2015). Age and sex variation in serum albumin concentration: an observational study. Annals of Clinical Biochemistry International Journal of Laboratory Medicine, 53(1), 106–111. https://doi.org/10.1177/0004563215593561

Gonzalez, Z., Loganathan, P., Sarosiek, I., & McCallum, R. W. (2020). Gender-Related differences in gastroparesis. The American Journal of the Medical Sciences, 360(5), 474–483. https://doi.org/10.1016/j.amjms.2020.04.018

Gangula, P. R., Sekhar, K. R., & Mukhopadhyay, S. (2011). Gender bias in gastroparesis: is nitric oxide the answer?. Digestive diseases and sciences, 56(9), 2520–2527. https://doi.org/10.1007/s10620-011-1735-6

Watson, S., Caster, O., Rochon, P. A., & Ruijter, H. D. (2019). Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine, 17, 100188. https://doi.org/10.1016/j.eclinm.2019.10.001

Carmina, E., & Longo, R. A. (2023). Semaglutide Treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. Journal of Clinical Medicine, 12(18), 5921. https://doi.org/10.3390/jcm12185921

Tran, M., Swartz, N., & Elisèe, S. D. (2025). Refractory dysmenorrhea managed with a Glucagon-Like peptide-1 agonist: a case report. Cureus. https://doi.org/10.7759/cureus.77387

Ogunremi, O. O., Ismail, S. F., Dhami, R. K., Newton, J. S., Kindle, S. A., & Kozmenko, V. (2024). A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists. International Journal of Women’s Dermatology, 10(2), e143. https://doi.org/10.1097/jw9.0000000000000143

Gabrielle M. Grasso. (2025). GLP-1 receptor agonists associated with acne vulgaris in women. Healio. Retrieved from https://www.healio.com/news/dermatology/20250304/glp1-receptor-agonists-associated-with-acne-vulgaris-in-women

Sodhi, M., Rezaeianzadeh, R., Kezouh, A., Frey, C., & Etminan, M. (2025). Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. medRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2025.02.23.25322568

Alzahrani, W. S., Bahkali, S. A., Alharthy, R. F., & Alsabban, A. S. (2025). Alopecia areata following semaglutide treatment for weight loss: a case report. JAAD Case Reports. https://doi.org/10.1016/j.jdcr.2025.06.012

Tobaiqy, M., & Elkout, H. (2024). Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. International Journal of Clinical Pharmacy, 46(2), 488–495. https://doi.org/10.1007/s11096-023-01694-7

Li, J., Cao, J., Wei, J., & Geng, W. (2023). Case Report: Semaglutide-associated depression: a report of two cases. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1238353

Kolding, L., Henriksen, J. N., Sædder, E. A., Ovesen, P. G., & Pedersen, L. H. (2025). Pregnancy outcomes after semaglutide exposure. Basic & Clinical Pharmacology & Toxicology, 136(4). https://doi.org/10.1111/bcpt.70021